C4 Therapeutics, Inc. — Director's Dealing 2023

Feb 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2023-02-13

Reporting Person: White Lauren (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-13	Common Stock	A	26000	—	Acquired	31097	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-13	Stock Option (Right to Buy)	$5.67	A	125000	Acquired	2033-02-12	Common Stock (125000.0)	Direct

Footnotes

F1: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024.

F2: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023.